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Yu Huang1†, Qing He1,2,4*†, Min Yang2,3 and Lei Zhan2Abstract
Introduction: Antiarrhythmia agents have been used in the treatment of cardiac arrest, and we aimed to review
the relevant clinical controlled trials to assess the effects of antiarrhythmics during cardiopulmonary resuscitation.
Methods: We searched databases including Cochrane Central Register of Controlled Trials; MEDLINE, and EMBASE.
Clinical controlled trials that addressed the effects of antiarrhythmics (including amiodarone, lidocaine, magnesium,
and other new potassium-channel blockers) on the outcomes of cardiac arrest were included. Data were collected
independently by two authors. The risk ratio of each outcome was collected, and meta-analysis was used for data
synthesis if appropriate. Heterogeneity was assessed with the χ2 test and the I2 test.
Results: Ten randomized controlled trials and seven observational trials were identified. Amiodarone (relative risk
(RR), 0.82; 95% confidence interval (CI), 0.54 to 1.24), lidocaine (RR, 2.26; 95% CI, 0.93to 5.52), magnesium (RR, 0.82;
95% CI, 0.54 to 1.24) and nifekalant were not shown to improve the survival to hospital discharge compared with
placebo, but amiodarone, lidocaine, and nifekalant were shown to be beneficial to initial resuscitation, assessed by
the rate of return of spontaneous circulation and survival to hospital admission, with amiodarone being superior
to lidocaine (RR, 1.28; 95% CI, 0.57 to 2.86) and nifekalant (RR, 0.50; 95% CI, 0.19 to 1.31). Bretylium and sotalol were
not shown to be beneficial.
Conclusions: Our review suggests that when administered during resuscitation, antiarrhythmia agents might not
improve the survival to hospital discharge, but they might be beneficial to initial resuscitation. This is consistent
with the AHA 2010 guidelines for resuscitation and cardiovascular emergency, but more studies with good
methodologic quality and large numbers of patients are still needed to make further assessment.
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Sudden cardiac arrest (SCA) is an emergency with high
incidences but poor outcomes. Summary data indicate
that the annual incidence of emergency medical service
(EMS)-treated out-of-hospital cardiac arrest (OHCA) is
about 50 to 55 per 100,000 persons in North America,
and the annual incidence of in-hospital cardiac arrest
(IHCA) ranges from three to six per 1,000 admissions.
Fewer than 10% of them have been survived to dis-
charge [1-4].* Correspondence: kk555888@126.com
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reproduction in any medium, provided the orFor the victims presenting with ventricular fibrillation
(VF)/pulseless ventricular tachycardia (VT), antiarrhythmia
agents are a kind of fundamental medication recommen-
ded by the resuscitation guidelines [5,6]. Some clinical tri-
als studied the effects of antiarrhythmics on the outcomes
of cardiac arrest. The number of participants in each study
might be limited, and the individual studies might be
different in methodologic quality, according to the study
designs and methods. Several variables should be consi-
dered when evaluating the effects of resuscitation drugs,
such as the scene of collapse or the quality of cardiopulmo-
nary resuscitation (CPR). Although some antiarrhythmics
have been recommended by the guidelines [5,6], evidence
does not indicate that they could increase the survival from
cardiac arrest, and more data are needed for the assess-
ments of these drugs administered during CPR.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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CPR currently, such as amiodarone, lidocaine, and mag-
nesium, we also supposed that the new potassium-
channel blockers (such as ibutilide and so on), which
emerged as important kinds of agents for various ar-
rhythmias, might have the potential to be used during
CPR [7-9]. Although reviews about antiarrhythmics used
during CPR were undertaken as part of the ILCOR
Consensus on CPR Science in 2010, however, new stu-
dies conducted after 2010 and also some new drugs were
not included, and no meta-analyses were performed to
evaluate the results quantitatively. Thus, we conducted
the systematic review and meta-analysis to review the
current literature, assess the relevant clinical trials quan-
titatively and qualitatively, and provide better evidence
regarding the effects of antiarrhythmia agents on the
outcomes of cardiac arrest.Methods
Study eligibility
We indentified studies according to the following criteria:
the studies were randomized controlled designs or pro-
spective/retrospective cohort designs; the studies recruited
adult (older than 18 years) cardiac arrest patients (OHCA
and IHCA); all arrest rhythms were included; antiarrhyth-
mic agents were administered during advanced cardiac
life support (ACLS), including amiodarone, lidocaine,
magnesium, other new potassium-channel blockers,
such as nifecalant, ibutilide, dofetilide, and others, such
as bretylium.
The studies had reported the following outcomes:
ROSC; short-term survival: survival to hospital intensive
care unit (ICU) admission for OHCA patients/survival
to 24 hours for IHCA patients; survival to hospital dis-
charge; and neurologic outcomes at discharge. Neurologic
outcomes at hospital discharge were measured as cerebral
performance category (CPC): good recovery (defined as a
CPC score of 1 or 2) and unfavorable recovery (defined as
a CPC score of 3, 4, or 5).Data sources
We searched the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE (Ovid), and EMBASE. We
also screened the reference lists of relevant trials and
reviews. We searched the following databases for unpub-
lished or ongoing studies: http://www.controlled-trials.
com and http://clinicaltrials.gov.
We searched the combination of the keywords “heart
arrest,” “sudden death,” “cardiopulmonary resuscitation,”
“tachycardia, ventricular,” “ventricular fibrillation,” “arrhy-
thmias, cardiac,” “advanced life support,” “antiarrhythmia
agents,” “amiodarone,” “lidocaine,” “magnesium,” and “po-
tassium-channel blockers.”The searching was performed in October 2012, for all
studies published in English between January 1948 and
October 2012.
Study selection and data extraction
Two authors (Yu Huang and Qing He) independently
screened all the titles and abstracts for eligibility. If we
doubted whether a title or abstract should be included
or excluded, then we read the full text to make a decision.
The full texts were also read independently. Disagree-
ments were solved by discussion with other authors, if any
(Min Yang and Lei Zhan).
Two authors (Yu Huang and Qing He) extracted and
collected data independently. The following data were
abstracted: publication information mainly including
first author’s last name and publication year; the settings
of the study; the study design; characteristics of types of
the included patients and the rhythms of arrest; infor-
mation about sample collecting; the regimens of drug
administration; and outcomes reported. Disagreements
were resolved by discussion.
Quality assessment of included studies
We assessed the methodologic quality of eligible trials by
using the Risk of Bias tool recommended by the Cochrane
Collaboration [10]. We assessed each trial across the fol-
lowing quality domains: (a) random-sequence generation;
(b) allocation concealment; (c) blinding: according to spe-
cial properties of CPR, we considered blinding adequate if
the professional rescuers, the physicians in the hospital or
the intensive care unit and the outcome assessors were
blinded, regardless of the blinding of patients; (d) incom-
plete outcome data or loss to follow-up; and (e) selective
reporting and any other potential threats to validity.
The assessment was performed by two authors (YuHuang
andQingHe) independently.
Synthesis of results
The ROSC and survival outcomes were measured and
derived as risk ratios (RRs) with 95% confidence inter-
vals (CIs). Neurologic outcomes, grouped into the two
categories of good recovery and unfavorable recovery,
were also measured as RR with 95% CI to adapt them
for meta-analysis. We synthesized the data by meta-
analysis if available. Meta-analysis was performed by
using Review Manager (RevMan 5.1). Heterogeneity was
tested by using the χ2 test, and P ≤ 0.10 was considered
significant. The I2 statistic also was used (I2% ≤ 25% for
low, 25% < I2% < 50% for moderate, and I2% ≥ 50% for
high). According to the variability of practice of CPR,
including the different comorbidities of the included
patients, the different treatment strategies and so on, we
expected that a random-effects model would be suitable
for this meta-analysis.
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We planned to perform subgroup analysis of OHCA and
IHCA patients when applicable.
Sensitivity analysis
We planned to perform sensitivity analysis by excluding
trials with high risk of bias when applicable.
Results
Our broad search identified 1,583 studies, and finally 14
were included after abstract screening and full-text
reviewing (Figure 1) [11-24]. After analysis, we broadly
categorized the studies into the following questions:
antiarrhythmia agents (amiodarone/lidocaine/magnesium
sulfate) versus placebo; amiodarone versus lidocaine;
nifekalant versus lidocaine/amiodarone; and other drugs.
Antiarrhythmia agents versus placebo
We identified eight eligible studies that compared the
effects of antiarrhythmia agents versus placebo for car-
diac arrest. Five of the included studies were randomized
designed trials, and the other three were retrospective
observational studies [11-18]. The details of study cha-
racteristics are shown in Table 1.
One randomized controlled trial studied the use of
amiodarone during CPR, and 504 patients were enrolled.
Kudenchuk and colleagues performed a study conducted
in urban and suburban emergency medical service
(EMS) systems in the United States [11]; the CPR pro-
tocol was according to American Heart Association
(AHA) guidelines published in 1982. OHCA patients
(504) were enrolled, and 300 mg amiodarone or placebo
was administered randomly if no resuscitation was
gained after three shocks. The rescuers responsible for
drug administration, advanced life support (ALS), orFigure 1 Flow diagram of literature search.treatment in the emergency department (ED), and the
investigators responsible for data collection and analyses,
were all blinded adequately. The recipients of amiodarone
were more likely to be resuscitated and survive to admis-
sion (RR, 1.27; 95% CI, 1.02 to 1.59); however, the propor-
tion of patients who survived to discharge did not differ
significantly in the two groups (RR, 1.02; 95% CI, 0.65 to
1.59). Thus although ROSC was not reported, amiodarone
had significantly improved initial resuscitation compared
with placebo, according to survival to hospital admission.
Another retrospective study conducted by the Helsinki
EMS systems studied the use of undiluted amiodarone
in the management of VF/pulseless VT resistant to three
shocks [12]. No significant differences were shown in
ROSC, survival to hospital admission, and discharge, but
data demonstrated that the patients who received amio-
darone had a more complicated prehospital course com-
pared with those who did not receive amiodarone.
Four trials studied the effects of magnesium for car-
diac arrest [13-16]; all were double-blinded randomized
controlled trials. Three trials enrolled 370 OHCA pa-
tients [13-15]. In the case of Hassan et al. [13], the study
was conducted in the county of Leicestershire, UK, and
CPR was performed according to ERC guidelines pub-
lished in 1992. Patients who had either VF resistant to
three shocks or a second episode of VF during resusci-
tation were included. Magnesium sulfate (2 g) or placebo
was given intravenously, and a repeated dose of 2 g mag-
nesium sulfate might be given after six ineffective shocks.
In the case of Allegra et al. [14], a multicenter prehospital
study clinical trial conducted in New Jersey, USA. was
found. Patients with VF refractory to three shocks were
included, and magnesium sulfate (2 g) or placebo was
given intravenously. In the case of Fatovich et al. [15], the
study was undertaken at the ED of a large university
Table 1 Study characteristics
Study design Setting and sample size Inclusion of participants Intervention Control Reported outcomes
Kudenchuk et al. [11] Randomized, double-
blind, placebo-
controlled study
Conducted in urban and
suburban emergency medical
service (EMS) systems in US, CPR
was performed following the
treatment protocols written in
accordance with American Heart
Association guidelines for advanced
cardiac life support (ACLS) in 1982;
504 participants were enrolled
Adults with nontraumatic out-of-
hospital cardiac arrest were eligible
if ventricular fibrillation or pulseless
ventricular tachycardia (on initial
presentation or any time in the
course of the resuscitation attempt)
was present after three or more
precordial shocks









Skrifvars et al. [12] Retrospective
designed study
Conducted by Helsinki EMS systems;
CPR was performed according to
2000 guidelines; 180 patients were
enrolled
Adult OHCA patients with VF/
pulseless VT resistant to three
shocks











Fatovich et al. [15] Double-blind,
randomized
controlled study
Undertaken at the ED of Royal Perth
Hospital which served a population
of 400,000 residents in urban setting;
CPR was performed in accordance
with the guidelines for clinical trials
published by the Australian National
Health and Medical Research
Council; 67 patients were enrolled
All victims of OHCA receiving CPR,
brought to the ED by the EMS
system were eligible. Patients were
excluded if they were already dead,
not receiving CPR, already
successfully resuscitated, or if the
cardiac arrest was due to a
noncardiac etiology
5 g MgSO4 (20 M in
10 ml), given as a bol
10 ml 0.9% normal




Thel et al. [16] Double-blind,
randomized
controlled study
Conducted by the Duke Hospital
code team, CPR was performed
according to the American Heart
Association guidelines for ACLS;
152 participants were enrolled
All hospital inpatients in the
intensive-care units and general
wards who were at least 18 years
old and treated for cardiac arrest
by the Duke Hospital code team
were eligible
2 g bolus of
magnesium sulfate
followed by an infusio
of 8 g over 24-hour
period







Allegra et al. [14] Double-blind,
randomized
controlled study
Multicenter prehospital study clinical
trial conducted in NJ, USA; standard
ACLS algorithm was followed; 109
patients were enrolled
All patients with nontraumatic
cardiac arrest who were 18 years of
age or older and had VF refractory
to three electroshocks





Hassan et al. [13] Double-blind,
randomized
controlled study
Undertaken by the Leicestershire
Ambulance and Paramedic Service
which provided prehospital care to
approximately 900,000 people in
urban settings; CPR was performed
according to ERC guidelines in 1992;
105 patients were enrolled
All adult patients (older than
18 years) with prehospital CA
treated by EMS or in CA on arrival
in the emergency department. The
patient had either VF resistant to
three shocks or a second episode of
VF during a resuscitation cycle. CA
patients related to trauma, hanging,
or drowning were excluded
Magnesium sulfate
(2 g or 8 mM) repeate
with a further 2 g if th











Harrision [17] Retrospective design Undertaken by EMS in urban and
rural counties; 116 patients were
enrolled
Adult patients with shock-resistant
VF/VT
























Table 1 Study characteristics (Continued)
Herlitz et al. [18] Retrospective design Conducted by two city hospitals in
urban settings; 290 patients were
enrolled
Adult cardiac-caused OHCA patients
with VF/VT resistant to three shocks
50 mg lidocaine was
given intravenously
(could be repeated up
to 200 mg)




Dorian et al. [19] Randomized, double-
blind, placebo-
controlled study
The study was conducted under the
auspices of, a multitiered out-of-
hospital emergency-response system
in Toronto; treatment protocols were
in accordance with the American
Heart Association guidelines for
advanced cardiac life support; 347
participants were enrolled
Adult patients with nontraumatic
out-of-hospital VF/other cardiac
rhythms that converted to VF, VF
was resistant to three shocks from
an external defibrillator, at least one
dose of intravenous epinephrine,





rapidly into a peripheral
vein
Lidocaine (1.5 mg/kg at
a concentration of
10 mg/ml), infused






Rea et al. [20] Multicenter
retrospective cohort
study
Undertaken in three academic
medical centers in the United States;
CPR treatments and drug doses were
according to 2000 AHA guidelines;
118 patients were enrolled
Patients experienced in-hospital
cardiac arrest secondary to pulseless
VT/VF were included. Pregnant
women, prisoners, and patients








the 2000 AHA guidelines
Survival to 24 hours;
survival to hospital
discharge
Amino et al. [21] Retrospective
observational study
Conducted by EMS system of Tokai
University. The CPR protocol was
adapted from ACLS algorithm
recommended by AHA; 30 patients
were enrolled
Adult out-of-hospital cardiac arrest
patients with first defibrillation failure
or VF recurrence were included
Nifekalant Amiodarone ROSC; survival to
admission; survival to
hospital discharge
Igarashi et al. [24] Retrospective
observational design
Conducted by Toho Omori
University Hospital; 22 patients were
enrolled
Adult out-of-hospital cardiac arrest
patients with VF and unsuccessful
defibrillation attempts by paramedics
Nifekalant(0.2-0.4 ml/kg) Lidocaine(1–2 mg/kg) ROSC; survival to
discharge
Tahara et al. [23] Retrospective, historic
controlled design
Undertaken in urban settings in
Yokohama, Japan; CPR treatments
were according to 2000 AHA
guidelines; 120 patients were enrolled
Patients who had out-of-hospital VF
and were transferred to the
university hospital, VF persisted after
three shocks and a dose of








Shiga et al. [22] Prospective
observational study
Conducted in the cardiology
departments of 10 hospitals in urban
settings
Adult patients with VF when
admitted to hospital
Nifekalant Amiodarone ROSC; short-term
survival; survival to
discharge
Nowak et al. [26] Double-blinded,
randomized
CPR treatments were consistent with
American Heart Association protocols
OHCA patients 10 mg/kg of bretylium Placebo Survival to emergency
department leaving
Olson et al. [25] Randomized study Conducted with the Milwaukee
County Paramedic system
OHCA patients with refractory VF 5-10 mg/kg bretylium 1 mg/kg lidocaine Survival to admission;
survival to discharge
Kovoor et al. [27] Randomized, double-
blinded study
Conducted with the Ambulance
Service of New South Wales
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were still undergoing arrest when they arrived at the ED,
and the patient management followed standard ALS
guidelines (5 mg MgSO4 or 10 ml saline was given ran-
domly at arrival at the ED). These three individual studies
showed that no significant differences were found between
magnesium and placebo groups in either ROSC or sur-
vival to discharge.
One trial was conducted by the Duke Hospital code
team, and enrolled 67 IHCA patients from intensive care
or general wards [16]. The primary diagnosis included
circulatory/neurologic/respiratory disorders. The resus-
citation protocol was according to AHA guidelines,
MgSO4 (2-g bolus followed by an infusion of 8 g over a
24–hour period) or placebo given in a double-blinded
manner. The results showed that in IHCA patients, no
significant differences occurred between the magnesium
and placebo groups in all outcomes.
Two retrospective studies compared lidocaine with
placebo for OHCA patients with shock-resistant VF/VT
[17,18]. In total, 406 patients were enrolled, and either
individual study showed that lidocaine was superior to
placebo in initial resuscitation but not survival to
discharge.
We assessed the quality of the evidence by using the
Cochrane Risk of Bias tool (see details in Table 2). In the
five randomized trials, random sequence was generated
by computer in the case of Allegra et al. [14], but no
detailed information about the allocation concealment
was found in the text. Sealed envelopes and central allo-
cation were used for allocation in the case of Fatovich
et al. [15], but no detailed information on randomized
sequence generation was reported. No detailed informa-
tion about random-sequence generation and allocation
concealment could be found in the articles about other
studies [11,13,16]. However, they are all randomized
prospective designs, according to the texts, so unclear
selection bias was considered [11,13-16]. Double-blinding
was performed in all trials [11,13-16], and in the case of
Kudenchuk et al. [11], the rescuers in the ED and the
investigators for data collection and analyses were also
blinded. Because considering the blinding of outcome
assessors would not influence the analysis of ROSC or
survival rate, a low risk of performing bias was considered.
In the three retrospective studies, high risk of allocation
and performing bias was considered [12,17,18]. Moreover,
low risk of attribution and other bias was considered in all
studies.
We performed meta-analysis by subgroups according
to the different antiarrhythmics (Figures 2, 3, and 4).
The rates of survival to hospital discharge were reported
in all trials, whereas the other two outcomes were not.
The pooled results showed that none of amiodarone
(χ2 = 1.80; P = 0.18; I2 = 45%; RR, 0.82; 95% CI, 0.54to 1.24) magnesium (χ2 = 0.89; P = 0.83; I2 = 0; RR,1.07;
95% CI, 0.62 to 1.86) or lidocaine (χ2 = 1.16; P = 0.28;
I2 = 14%; RR, 2.26; 95% CI, 0.93 to 5.52) had improved the
survival to discharge. In the evaluation of outcomes of
initial resuscitation, no difference was found in ROSC and
survival to admission/24 hours between magnesium and
placebo, but lidocaine was shown to improve initial resus-
citation, according to the pooled results.
No trials reported data of neurologic outcomes assessed
with CPC, so no meta-analysis was performed. In addi-
tion, only two trials reported data of neurologic outcomes
measured by Glasgow Coma Scale score in OHCA and
IHCA patients [13,16], and both trials showed that mag-
nesium had not improved neurologic outcomes at hospital
discharge compared with placebo.
Amiodarone versus lidocaine
Two studies compared the effects of amiodarone and
lidocaine during CPR (Table 1) [19,20]. Dorian and col-
leagues [19] performed a randomized study conducted
under the auspices of the Toronto EMS system, and 247
patients were enrolled. OHCA patients with VF/pulseless
VT refractory to defibrillation shocks were included, and
the CPR was performed based on the 2000 AHA guide-
lines. Amiodarone (5 mg/kg) or lidocaine (1.5 mg/kg)
was administered in a randomized, double-blinded man-
ner. If VF persisted after a further shock, a second dose
was given (1.5 mg/kg lidocaine; 2.5 mg/kg amiodarone),
and resuscitation was continued. The rate of survival to
admission was significantly higher in the amiodarone
group compared with the lidocaine group (RR, 1.90; 95%
CI, 1.16 to 3.11), however, no significant difference was
found in the survival to discharge between the two
groups (RR, 1.67; 95% CI, 0.57 to 4.88). Rea and col-
leagues [20] retrospectively reviewed the data of IHCA
(pulseless VT/VF) from three large academic medical
centers. Cardiac arrest was caused by circulatory or
respiratory diseases. All CPR treatments and drug doses
were according to 2000 AHA guidelines. The results
showed that no difference was found in the proportion
of patients alive 24 hours after arrest and at discharge
between the two groups, the survival to ICU admission
was reported. However, amiodarone was administered
8 minutes later on average, compared with lidocaine.
In Dorian et al. [19], adequate allocation concealment
and binding was considered, according to the article, but
no information about randomized-sequence generation
was reported, so unclear risk of selection bias was
considered. For the retrospective study [20], high risk of
selection, performing, and detection bias was considered.
Details are shown in Table 2.
Both of the two studies reported survival to discharge
and survival to admission. The pooled results showed
that no significant differences in survival to discharge
Table 2 Assessment methodologic quality





of bias across study
Kudenchuk et al. [11] Complete randomization was used
according to the text, no details reported
Lack of details reported Adequate Yes Yes Low risk of bias




Yes Yes High risk of bias
Fatovich et al. [15] Complete randomization was used
according to the text, no details reported
Adequately performed Adequate Yes Yes Low risk of bias
Thel et al. [16] Complete randomization was used
according to the text, no details reported
Performed according to the text,
lack of details reported
Adequate Yes Yes Low risk of bias
Allegra et al. [14] Random sequence generated by
computer
Performed according to the text,
lack of details reported
Adequate Yes Yes Low risk of bias
Hassan et al. [13] Complete randomization was used
according to the text, no details reported
Sealed envelopes were used for
allocation, adequate
Adequate Yes Yes Low risk of bias
Harrision [17] High risk of allocation bias was considered, according to the retrospective
design
No blinding Yes Yes High risk of bias




Yes Yes High risk of bias
Dorian et al. [19] Complete randomization was used
according to the text, no details reported
Adequately performed Adequate Yes Yes Low risk of bias




Yes Yes High risk of bias
Amino et al. [21] Randomized controlled design, but lack of detailed information, unclear risk
of allocation bias was considered
Blinding was performed,
but lack of details
Yes Yes Unclear risk of bias




Yes Yes High risk of bias




Yes Yes High risk of bias




Yes Yes High risk of bias
Nowak et al. [26] Randomization was performed, but lack
of details was found
Lack of details reported Double-blinding was
performed
Yes Yes Unclear risk of bias
Olson et al. [25] Randomization was performed, but lack
of details was found
Lack of details reported No blinding was
performed
Yes Yes Unclear risk of bias
Kovoor et al. [27] Quasi-randomization was considered,
according to the text
Adequately performed according
to the text, lack of details
Double-blinding was
performed













Figure 2 Comparison of the effects of antiarrhythmics versus placebo. Outcome: ROSC (return of spontaneous circulation). Subgroup
analysis was performed according to different medications.
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1.55) and also survival to admission (Figure 5).
Nifekalant versus amiodarone/lidocaine
In our review, we attempted to study the use of new
potassium-channel blockers during CPR, and only four
trials that studied the effects of nifekalant were identified
(Table 1) [21-24]. Amino and colleagues [21] compared
nifekalant versus amiodarone for OHCA patients
(shock-resistant VF) who were transferred to the EMS of
Tokai University [21]. Thirty patients were enrolled, and
the study drugs were given randomly; amiodarone was
shown to be superior to nifekalant in all outcomes
(Figure 6). Shiga and colleagues [22] conducted a pro-
spective observational study to compare the effects of
nifekalant versus lidocaine for IHCA (shock-resistant
VF/VT) [22]. Tahara and colleagues [23] performed a
retrospective, historical controlled study that enrolled
OHCA patients with shock-resistant VF. Both studies
showed that nifekalant significantly improved ROSC
compared with lidocaine but not the live discharge. Add-
itionally, Igarashi and colleagues [24] conducted a con-
trolled study with only 22 patients to compare nifekalant
and lidocaine for OHCA patients with VF. Nifekalant
(0.2 to 0.4 ml/kg) or lidocaine (1 to 2 mg/kg) was given
respectively after arrival at the ED and confirmation ofVF. All patients died before discharge, but nifekalant
was shown to improve the return of sinus rhythms com-
pared with lidocaine.
In the assessments of methodologic qualities (Table 2),
unclear risk of selection bias was considered for the ran-
domized trial, but high risk of selection and performing
bias was considered for the other two observational
studies [21-23]. In the case of Igarashi et al., because no
detailed information about study design was found in
the text, a high risk of bias was considered for this study
[24]. The overall pooled results showed that nifekalant
significantly improved initial resuscitation compared with
lidocaine (Figure 7), but no significant difference was
found in the live discharge between the two groups (χ2 =
0.59; P = 0.44; I2 = 0; RR, 1.40; 95% CI, 0.88 to 2.25).
Others
One randomized trial enrolled 91 out-of-hospital pa-
tients with VF refractory to four countershocks and
compared the effect of bretylium with lidocaine [25].
Bretylium was not shown to have better effect than
lidocaine on survival to hospital admission (RR, 1.01;
95% CI, 0.48 to 2.15) and survival to hospital discharge
(RR, 0.45; 95% CI, 0.09 to 2.18). Another randomized
double-blinded trial compared the effect of bretylium
with placebo [26]. Bretylium was not shown to improve
Figure 3 Comparison of the effects of antiarrhythmics versus placebo. Outcome: survival to hospital admission/24 hours. Subgroup analysis
was performed according to different medications.
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(RR, 4.28; 95% CI, 0.60 to 30.26).
In a randomized double-blinded trial of sotalol versus
lignocaine in out-of-hospital VF patients [27], 129 patients
with VF refractory to four shocks were enrolled, and the
results showed that sotalol was not superior to lignocaine
for improving survival to hospital admission (RR, 0.60;
95% CI, 0.33 to 1.10), survival to hospital discharge
(RR, 0.33; 95% CI, 0.07 to 1.52), and neurologic outcome
(RR, 0.13; 95% CI, 0.01 to 2.32).
Subgroup analysis
In the comparison of magnesium with placebo and
amiodarone with lidocaine, both OHCA and patients
were included, so we performed subgroup analysis of
OHCA and IHCA patients.
In the comparison of magnesium with placebo, three
double-blind, randomized controlled trials enrolled 281
OHCA patients, and magnesium was not shown to
improve survival to hospital discharge (RR, 1.57; 95% CI,
0.41 to 6.05), ROSC (RR, 1.16; 95% CI, 0.71 to 1.89), and
survival to ICU admission (RR, 0.92; 95% CI, 0.68 to
1.24) [13-15]. One double-blind, randomized controlled
trial enrolled 67 IHCA patients, and the results showedthat magnesium had not improve survival to hospital
discharge (RR, 0.99; 95% CI, 0.54 to 1.82), ROSC (RR,
0.90; 95% CI, 0.68 to 1.18), or survival to 24 hours
(RR, 1.16; 95% CI, 0.32 to 4.26) [16].
In the comparison of amiodarone with lidocaine, one
double-blind, randomized controlled trial with 347
patients showed that amiodarone improved the survival
to ICU admission (RR, 1.90; 95% CI, 1.16 to 3.11) in
OHCA patients compared with lidocaine [19]. However,
in IHCA patients, the other retrospective study that
enrolled 118 patients, showed no significant difference
in survival to 24 hours between the two treatments (RR,
0.91; 95% CI, 0.69 to 1.18) [20]. No significant difference
was found between the effects of amiodarone and
lidocaine on survival to hospital discharge (RR, 0.99;
95% CI, 0.54 to 1.82) in both OHCA and IHCA patients
[19,20].
Sensitivity analysis
In the comparisons of amiodarone with placebo and
amiodarone with lidocaine, only one trial could be
identified if the other trials with high risk of bias were
excluded [11,19]. In the comparison of amiodarone with
placebo, amiodarone was shown to improve ROSC rate
Figure 5 Comparison of the effects of amiodarone versus lidocaine. (A) Survival to hospital admission/24 hours. (B) Survival to
hospital discharge.
Figure 4 Comparison of the effects of antiarrhythmics versus placebo. Outcome: survival to hospital discharge. Subgroup analysis was
performed according to different medications.
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Figure 6 Comparison of nifekalant with amiodarone. (A) ROSC. (B) Survival to hospital admission/24 hours. (C) Survival to hospital discharge.
ROSC, return of spontaneous circulation.
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1.59) compared with placebo; however, the survival to
discharge did not differ significantly in the two groups
(RR, 1.02; 95% CI, 0.65 to 1.59) [11]. These results were
consistent with those synthesized before exclusion of the
retrospective designed study, which was considered to
be with high risk of bias.
In the comparison of amiodarone with lidocaine, when
the retrospective designed study with high risk of bias was
excluded, only one randomized blinded trial was included,
and no significant difference was found in the survival to
discharge between the two groups (RR, 1.67; 95% CI, 0.57
to 4.88), but the survival to admission was significantly
better in the amiodarone group compared with the lido-
caine group (RR, 1.90; 95% CI, 1.16 to 3.11) [19]. This was
not consistent with the totally pooled results. This result
might come from the design of two studies. In the retro-
spective designed study, no randomization and blinding
were performed, so high risk of selection bias and detec-
tion bias were considered. However, statistical heterogen-
eity (I2 = 88%) and clinical heterogeneity (the retrospective
designed study enrolled IHCA patients) were found.
Discussion
In our review, we included all adult nontraumatic patients.
The included studies were all conducted in urban orsuburban settings, and the medical treatment was
performed by European/American/Asian EMS systems or
EDs, respectively. The CPR treatment during ALS was
according to AHA or ERC guidelines published in 2000 or
before. The majority of participants’ rhythms were presen-
ted as VF/VT.
In the comparison of magnesium versus placebo, four
studies with good methodologic quality were included
[13-16], and no significant differences could be found in
ROSC, survival to admission, and survival to hospital
discharge between the two treatments. In subgroups of
OHCA and IHCA patients, no significant differences
were found in all outcomes. Although two trials
included few patients with other rhythms, we did not
perform subgroup analysis for these rhythms because of
such small sample size [15,16]. Thus, our results demon-
strate that magnesium has no significant benefits when
used for CPR, for either OHCA or IHCA.
In the assessments of the effects of amiodarone, no
improvement of survival to admission was found in
ROSC, survival to admission, and survival to hospital
discharge when treated with amiodarone according to the
pooled results. But when excluding a retrospective obser-
vational study, one randomized trial that had enrolled 504
patients and was considered to have good quality showed
that amiodarone had improved the survival to admission
Figure 7 Comparison of nifekalant versus lidocaine. (A) ROSC. (B) Survival to hospital admission/24 hours. (C) Survival to hospital discharge.
ROSC: return of spontaneous circulation.
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[11]. All high statistical (I2 = 86%), methodologic, and clin-
ical heterogeneity was concerned between the two studies
included in the synthesis. The heterogeneity derived from
the retrospective study with high risk of bias [12], and in
this study, the prehospital condition was more severe in
the amiodarone group [20]. So the pooled results of
survival to admission must be interpreted with caution.
According to the high-quality study [11], amiodarone is
still likely to be beneficial to initial resuscitation,
although the effect size is rather small (RR, 1.27; 95% CI,
1.02 to 1.59).
We also identified two studies that had compared
amiodarone with lidocaine. The pooled results showed
that no significant differences could be found in the
survival to hospital discharge and survival to admission/
24 hours between the two study groups. However, one
good-quality study indicated that amiodarone was super-
ior to lidocaine in initial resuscitation (evaluated by the
survival to admission) [19]. This was inconsistent with the
results reported from the other retrospective designed
study and also the pooled result [20]. According to sen-
sitivity analysis, the pooled results did not seem to berobust. However, the retrospective observational study
included IHCA patients, whereas the RCT included
OHCA patients, and it was considered to be with high risk
of bias. Moreover, in the observational study, amiodarone
was administered later than lidocaine, and it was not
administered with the recommended doses to all the
patients. So it is suggested that the reduced demonstrated
effects of amiodarone on survival to 24 hours in this study
is due to such clinical heterogeneity. Significant statistical
heterogeneity (I2 = 88%) was also considered between
these two studies. Thus, in the comparison of amiodarone
with lidocaine, the pooled result of the survival to admis-
sion still must be interpreted with caution. We generally
suggest the use of amiodarone instead of lidocaine,
according to the findings of the randomized trial.
Two studies with high risk of bias compared lidocaine
with placebo [17,18], and showed that no significant
differences were found in those alive at discharge
between the two groups. Although it is indicated that
lidocaine has the potential to improve initial resuscita-
tion compared with placebo, the quality of evidence is
low, and we suggest that the replacement of lidocaine
with amiodarone in clinical use seems to be appropriate.
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blockers might have the potential to be used during
CPR. However, after our literature search, no more trials
were identified, except for four trials that focused on the
effects of nifekalant, and they were all conducted in
Japan [21-24]. The pooled results of three low-quality
trials indicated that nifekalant was superior to lidocaine in
initial resuscitation but not in the survival outcomes
[22-24]. By contrast, a randomized trial with small sample
size showed that nifekalant was inferior to amiodarone in
either initial resuscitation or survival outcomes [21]. Thus,
no present evidence can support the use of such
potassium-channel blocker instead of amiodarone. Al-
though nifekalant may be superior to lidocaine in initial
resuscitation, considering the low quality of evidence, it is
still hard to suggest the use of nifekalant.
Some studies focused on the use of bretylium and
sotalol, but the very limited data showed no benefits of
the two drugs.
Above all, all antiarrhythmic drugs were not shown to
be significantly beneficial for cardiac arrest. However,
because many variables might affect the practice of
resuscitation, such as the cause of arrest, the response
interval of the EMS system, the chest-compression frac-
tion, the quality of CPR, and postresuscitation treatment.
Thus, regarding these issues, the retrospective design of
a study might bring high risk of overall bias through the
study, including allocation, performing, and detection
bias. All of these might have the potential to affect the
demonstration of treatment effect. Therefore, according
to the high-quality studies [11,19], it is suggested that
amiodarone still seems to be superior to placebo (RR,
1.27; 95% CI, 1.02 to 1.59) and lidocaine (RR, 1.90; 95%
CI, 1.16 to 3.11) for improving initial resuscitation
assessed by the survival to admission, although the effect
sizes are not big.
For the lack of data, we only performed subgroup
analysis according to OHCA and IHCA in the compari-
son of magnesium with placebo and amiodarone with
lidocaine. Similar results were found in both subgroups
in the comparison of magnesium with placebo for all
outcomes. Although in the comparison of amiodarone
with lidocaine, the results were not consistent in the two
subgroups in the analysis of initial resuscitation, this
inconsistence might derive from the nonrandomization
of the observational study.
Limitations in our review include that little evidence
can be found after searching the literature. In the sub-
groups of amiodarone versus placebo, amiodarone ver-
sus lidocaine, and nifekalant versus amiodarone, only
one or two controlled trials could be found. In total, 433
patients were included in the pooled results of the
subgroup of magnesium versus placebo. Therefore, the
results derived from present literature were ratherunderpowered to appraise certain ideas according to the
sample sizes.
The second limitation is related to the methodologic
quality of individual evidence. Many of the included
studies were observational cohort studies, and especially,
retrospective design. We suggest that adequate randomi-
zation and blinding of the rescuers is important to
reduce the allocation, performing, and detection bias in
clinical practice of CPR; thus, high risk of bias might be
considered for these individual observational studies.
The third limitation is related to the heterogeneity,
especially clinical heterogeneity, which is an inherent
problem in data synthesis. The emergency settings in the
rescuing from cardiac arrest bring particular difficulties
of access to the expected homogeneity in clinical studies.
The reviewed studies included patients with varied base-
line characteristics (such as the settings of collapse, basic
diagnosis, bystander CPR, CPR protocols performed by
professional rescuers, and different regimens of antiar-
rhythmics and postresuscitation care, such as hypother-
mia). Although no significant difference was found in
baseline characters between the study groups, all these
variables lead to clinical heterogeneity. Significant statis-
tical heterogeneity was found according to the χ2 test
and I2 statistic in subgroups. These encouraged us to use
a random-effect model.
So according to these issues, the pooled results of the
data from current evidence still need to be interpreted
with caution. We assessed the data according to sub-
groups of OHCA and IHCA, but conversely, the sample
size is rather weakened.
Our review provides some implications. To our know-
ledge, lack of evidence focused on medications during
CPR can be found. No antiarrhythmia agents have been
demonstrated to improve the survival of cardiac-arrest
patients. According to studies of high quality, only
amiodarone seems to be beneficial in the improvement
of initial resuscitation, although the strength of existing
evidence is not robust enough, according to the sample
size. Our review supports the summarization of the
effects of antiarrhythmics and the recommendation of
medication strategies in the AHA 2010 guidelines [5,6],
and we suggest the use of amiodarone in patients with
refractory VF/pulseless VT. A previous review provided
a similar implication. Compared with the review, we
performed a more up-to-date literature search; we also
used an optimized tool to assess the quality of evidence,
and we synthesized data by meta-analysis.
According to the review, a major issue of research in
resuscitation drugs is the lack of clinical data. It is im-
portant to develop randomized prospective studies with
large sample sizes to assess the effects of antiarrhythmia
agents during CPR. According to our review, nonrando-
mization and nonblinding design seem to bring a high
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affect the study results. Larabee et al. [28] suggested that
developing prospective regional/national systems for
analysis of cardiac arrest outcomes would be help to
capture an appropriate sample size to examine the medi-
cations and intended outcomes.
We suggest that it is important for the articles to
report details about the randomization or blinding
methods (such as allocation concealment) in resuscita-
tion studies, because in the research into resuscitation,
the details of randomization and blinding are important
in the assessment of the quality of evidence. Additionally,
no new drugs seem to be valuable in resuscitation
currently. Studies have not applied new antiarrhythmics to
resuscitation, such as other potassium-channel blockers,
but it is possible that these agents (such as ibutilide,
dofetilide) may have the potential to be used during CPR,
according to the pharmacologic mechanisms. Further
studies focusing on these agents might also be expected.
Conclusions
In summary, no current drugs have been shown to improve
the survival in cardiac-arrest patients. Only amiodarone
may improve initial resuscitation, and no new drugs can be
recommended currently. A major issue in resuscitation
research is that relevant studies focused on resuscitation
drugs are very limited, especially high-quality studies.
Key messages
 An up-to-date systemic review and meta-analysis
have found that according to present literature, only
limited data about the use of antiarrhythmic drugs for
cardiac arrest can be found, and the quality of
evidence is rather low. No antiarrhythmic drugs have
been shown to improve the survival of cardiac-arrest
patients, and only amiodarone is suggested to be used
for improving initial resuscitation by our review.
 More clinical studies focused on resuscitation drugs
are expected and warranted, especially studies with
good quality and focused on new types of
antiarrhythmic drugs.
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